Uric acid: Association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Nacak, Hakan ^a   Van Diepen, Merel ^a   De Goeij, Moniek C M ^a   Rotmans, Joris I ^a   Dekker, Friedo W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CKD progression; Pre dialysis; Prospective cohort; Uric acid

Indexed keywords

ALLOPURINOL; DIURETIC AGENT; LIPID; URIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; DEATH; DEMOGRAPHY; DIALYSIS; DIET RESTRICTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; BLOOD; CONTROLLED STUDY; HYPERURICEMIA; LONGITUDINAL STUDY; MIDDLE AGED; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERURICEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; URIC ACID;

EID: 84903772723     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-91     Document Type: Article

References (34)

1. Uric Acid, hypertension, and cardiovascular and renal complications. Zoccali C, Mallamaci F, Curr Hypertens Rep 2013 15 531 537
2. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW, Nephrol Dial Transplant 2014 29 406 413
3. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T, J Epidemiol 2000 10 403 409
4. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S, Am J Kidney Dis 2004 44 642 650 (Pubitemid 39237608)
5. Uric acid levels predict future development of chronic kidney disease. Sonoda H, Takase H, Dohi Y, Kimura G, Am J Nephrol 2011 33 352 357
6. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E, Diabetes Care 2012 35 99 104
7. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Siu YP, Leung KT, Tong MK, Kwan TH, Am J Kidney Dis 2006 47 51 59 (Pubitemid 41828266)
8. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A, Int Urol Nephrol 2007 39 1227 1233 (Pubitemid 350193621)
9. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Grayson PC, Kim SY, LaValley M, Choi HK, Arthritis Care Res (Hoboken) 2011 63 102 110
10. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Feig DI, Soletsky B, Johnson RJ, JAMA 2008 300 924 932
11. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. Agarwal V, Hans N, Messerli FH, J Clin Hypertens (Greenwich) 2013 15 435 442
12. Association of uric acid with change in kidney function in healthy normotensive individuals. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M, Am J Kidney Dis 2010 56 264 272
13. Elevated uric acid increases the risk for kidney disease. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R, J Am Soc Nephrol 2008 19 2407 2413
14. Hyperuricaemia and accelerated reduction in renal function. Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, Chou IJ, Chang HC, Chen HW, Yu KH, Scand J Rheumatol 2011 40 116 121
15. The association between plasma uric acid and renal function decline in a Chinese population-based cohort. Zhang L, Wang F, Wang X, Liu L, Wang H, Nephrol Dial Transplant 2012 27 1836 1839
16. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Park JT, Kim DK, Chang TI, Kim HW, Chang JH, Park SY, Kim E, Kang SW, Han DS, Yoo TH, Nephrol Dial Transplant 2009 24 3520 3525
17. EBPG guideline on dialysis strategies. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R, Nephrol Dial Transplant 2007 22 Suppl 2 i5 ii21
18. Multidisciplinary guidelines pre-dialysis. Dutch Federation of Nephrology, 2011
19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 1 S266
20. Measurement of renal function, when to refer and when to start dialysis. Section I, Nephrol Dial Transplant 2002 17 Suppl 7 7 15
21. A new equation to estimate glomerular filtration rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ann Intern Med 2009 150 604 612
22. FitzMaurice GM, Laird NM Hoboken, New Jersey: John Wiley & Sons, Inc 2011
23. Nonparametric estimation from incomplete observations. Kaplan EL, Meier P, J Am Stat Assoc 1958 53 282 457 481
24. Regression models and life-tables. Cox DR, J Royal Stat Soc 1972 34 2 187 220 Series B (Methodological)
25. Multiple imputation: dealing with missing data. de Goeij MC, Van DM, Jager KJ, Tripepi G, Zoccali C, Dekker FW, Nephrol Dial Transplant 2013 28 2 2415 2420
26. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J, Kidney Int 2005 67 237 247 (Pubitemid 40019245)
27. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M, Am J Physiol Renal Physiol 2007 292 1238 F1244
28. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodriguez-Iturbe B, Johnson RJ, Am J Physiol Renal Physiol 2008 295 1134 F1141
29. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ, Hypertension 2001 38 1101 1106 (Pubitemid 34252813)
30. Hyperuricemia causes glomerular hypertrophy in the rat. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ, Am J Nephrol 2003 23 2 7 (Pubitemid 35316757)
31. Uric acid and incident kidney disease in the community. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, J Am Soc Nephrol 2008 19 1204 1211
32. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, Exp Gerontol 2008 43 347 352
33. Uric acid and long-term outcomes in CKD. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V, Am J Kidney Dis 2009 53 796 803
34. Unreferred chronic kidney disease: a longitudinal study. John R, Webb M, Young A, Stevens PE, Am J Kidney Dis 2004 43 825 835 (Pubitemid 38529620)